Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib vs Talazoparib plus Atezolizumab after Palbociclib-Endocrine Therapy in Premenopausal HR+/HER2- Metastatic Breast Cancer with HRD
KCT0006190Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Talazoparib monotherapy with Talazoparib plus Atezolizumab (2 arms). Planned start Aug 2021; status: not yet recruiting.
02
Drugs
talazoparibatezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0006190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006190.